Mechanical circulatory support in severe heart failure: Single-center experience

E. Vitali, M. Lanfranconi, G. Bruschi, E. Ribera, A. Garatti, T. Colombo, C. F. Russo

Research output: Contribution to journalArticle

Abstract

Ventricular assist devices (VADs) have become important therapeutic tools to treat patients with end-stage cardiac failure. VADs are an essential component of transplantation programs as they successfully bridge individuals who would otherwise die. Recently left ventricular VAD (LVAD) therapy has been proposed as alternative to heart transplantation (HTx) for patients who are not transplant candidates. Other indications have now expanded into areas such as postcardiotomy failure, acute myocarditis, and acute massive myocardial infarction. From 1988 to May 2003, 80 patients received left or biventricular mechanical circulatory support including 78 as a bridge to and two as an alternative to HT. All patients survived the operation. Mean duration of VAD support was 77 ± 150 days. Fifty-one points (63.8%) underwent heart transplantation; 3 (3.8%) recovered and were weaned from VADs. Major bleeding episodes occurred in 11 patients (13.8%) and major neurologic events occurred in 8 (10%). Sixteen patients (20%) were discharged home while waiting for HTx. Twenty-two patients (27.5%) died on VAD. In conclusion, VAD therapy proved effective in bridging patients with end-stage heart failure to HTx. While on LVAD support patients who were assisted with implantable wearable devices could be discharged at home, improving their quality of life.

Original languageEnglish
Pages (from-to)620-622
Number of pages3
JournalTransplantation Proceedings
Volume36
Issue number3
DOIs
Publication statusPublished - Apr 2004

Fingerprint

Heart-Assist Devices
Heart Failure
Heart Transplantation
Myocarditis
Nervous System
Therapeutics
Transplantation
Myocardial Infarction
Quality of Life
Hemorrhage
Transplants
Equipment and Supplies

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Mechanical circulatory support in severe heart failure : Single-center experience. / Vitali, E.; Lanfranconi, M.; Bruschi, G.; Ribera, E.; Garatti, A.; Colombo, T.; Russo, C. F.

In: Transplantation Proceedings, Vol. 36, No. 3, 04.2004, p. 620-622.

Research output: Contribution to journalArticle

Vitali, E, Lanfranconi, M, Bruschi, G, Ribera, E, Garatti, A, Colombo, T & Russo, CF 2004, 'Mechanical circulatory support in severe heart failure: Single-center experience', Transplantation Proceedings, vol. 36, no. 3, pp. 620-622. https://doi.org/10.1016/j.transproceed.2004.02.050
Vitali, E. ; Lanfranconi, M. ; Bruschi, G. ; Ribera, E. ; Garatti, A. ; Colombo, T. ; Russo, C. F. / Mechanical circulatory support in severe heart failure : Single-center experience. In: Transplantation Proceedings. 2004 ; Vol. 36, No. 3. pp. 620-622.
@article{15bebd78949a462dada42b18cbcfefe6,
title = "Mechanical circulatory support in severe heart failure: Single-center experience",
abstract = "Ventricular assist devices (VADs) have become important therapeutic tools to treat patients with end-stage cardiac failure. VADs are an essential component of transplantation programs as they successfully bridge individuals who would otherwise die. Recently left ventricular VAD (LVAD) therapy has been proposed as alternative to heart transplantation (HTx) for patients who are not transplant candidates. Other indications have now expanded into areas such as postcardiotomy failure, acute myocarditis, and acute massive myocardial infarction. From 1988 to May 2003, 80 patients received left or biventricular mechanical circulatory support including 78 as a bridge to and two as an alternative to HT. All patients survived the operation. Mean duration of VAD support was 77 ± 150 days. Fifty-one points (63.8{\%}) underwent heart transplantation; 3 (3.8{\%}) recovered and were weaned from VADs. Major bleeding episodes occurred in 11 patients (13.8{\%}) and major neurologic events occurred in 8 (10{\%}). Sixteen patients (20{\%}) were discharged home while waiting for HTx. Twenty-two patients (27.5{\%}) died on VAD. In conclusion, VAD therapy proved effective in bridging patients with end-stage heart failure to HTx. While on LVAD support patients who were assisted with implantable wearable devices could be discharged at home, improving their quality of life.",
author = "E. Vitali and M. Lanfranconi and G. Bruschi and E. Ribera and A. Garatti and T. Colombo and Russo, {C. F.}",
year = "2004",
month = "4",
doi = "10.1016/j.transproceed.2004.02.050",
language = "English",
volume = "36",
pages = "620--622",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Mechanical circulatory support in severe heart failure

T2 - Single-center experience

AU - Vitali, E.

AU - Lanfranconi, M.

AU - Bruschi, G.

AU - Ribera, E.

AU - Garatti, A.

AU - Colombo, T.

AU - Russo, C. F.

PY - 2004/4

Y1 - 2004/4

N2 - Ventricular assist devices (VADs) have become important therapeutic tools to treat patients with end-stage cardiac failure. VADs are an essential component of transplantation programs as they successfully bridge individuals who would otherwise die. Recently left ventricular VAD (LVAD) therapy has been proposed as alternative to heart transplantation (HTx) for patients who are not transplant candidates. Other indications have now expanded into areas such as postcardiotomy failure, acute myocarditis, and acute massive myocardial infarction. From 1988 to May 2003, 80 patients received left or biventricular mechanical circulatory support including 78 as a bridge to and two as an alternative to HT. All patients survived the operation. Mean duration of VAD support was 77 ± 150 days. Fifty-one points (63.8%) underwent heart transplantation; 3 (3.8%) recovered and were weaned from VADs. Major bleeding episodes occurred in 11 patients (13.8%) and major neurologic events occurred in 8 (10%). Sixteen patients (20%) were discharged home while waiting for HTx. Twenty-two patients (27.5%) died on VAD. In conclusion, VAD therapy proved effective in bridging patients with end-stage heart failure to HTx. While on LVAD support patients who were assisted with implantable wearable devices could be discharged at home, improving their quality of life.

AB - Ventricular assist devices (VADs) have become important therapeutic tools to treat patients with end-stage cardiac failure. VADs are an essential component of transplantation programs as they successfully bridge individuals who would otherwise die. Recently left ventricular VAD (LVAD) therapy has been proposed as alternative to heart transplantation (HTx) for patients who are not transplant candidates. Other indications have now expanded into areas such as postcardiotomy failure, acute myocarditis, and acute massive myocardial infarction. From 1988 to May 2003, 80 patients received left or biventricular mechanical circulatory support including 78 as a bridge to and two as an alternative to HT. All patients survived the operation. Mean duration of VAD support was 77 ± 150 days. Fifty-one points (63.8%) underwent heart transplantation; 3 (3.8%) recovered and were weaned from VADs. Major bleeding episodes occurred in 11 patients (13.8%) and major neurologic events occurred in 8 (10%). Sixteen patients (20%) were discharged home while waiting for HTx. Twenty-two patients (27.5%) died on VAD. In conclusion, VAD therapy proved effective in bridging patients with end-stage heart failure to HTx. While on LVAD support patients who were assisted with implantable wearable devices could be discharged at home, improving their quality of life.

UR - http://www.scopus.com/inward/record.url?scp=2042536710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2042536710&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2004.02.050

DO - 10.1016/j.transproceed.2004.02.050

M3 - Article

C2 - 15110613

AN - SCOPUS:2042536710

VL - 36

SP - 620

EP - 622

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 3

ER -